Status:

RECRUITING

Continuous Effect Of Rehabilitation Training On Pulmonary Arterial Hypertension Patients

Lead Sponsor:

RenJi Hospital

Collaborating Sponsors:

Shanghai Pulmonary Hospital, Shanghai, China

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Conditions:

Pulmonary Hypertension

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

This multicenter, open label, double-arm study aims at investigating the the continuous effect of long-Term rehabilitation training on clinical improvement(ITTCI) and cardiopulmonary function in pulmo...

Detailed Description

Pulmonary Arterial Hypertension (PAH) is a disease caused by various reasons leading to pulmonary vascular remodelling and then results in a progressive increase in pulmonary vascular resistance and r...

Eligibility Criteria

Inclusion

  • Patients who suffered from pre-capillary PAH (mPAP ≥ 20 mmHg, PVR \> 2 Woods unit, PAWP ≤ 15 mmHg) confirmed by right heart catheterisation.
  • Patients who are in the status of WHO-FC I-III.
  • Patients between 18 and 75 years old
  • Female subjects are not pregnant.
  • Patients are treated with PAH-targeted drugs and are in a stable state and there is no progress of disease).
  • Patients have not received exercise rehabilitation training within six months.

Exclusion

  • Patients with the following diseases or symptoms:
  • Pulmonary vascular occlusive disease
  • Respiratory diseases
  • Ischaemic heart disease, complex congenital heart disease (e.g., tetralogy of Fallot, etc.), cardiomyopathy, valvular disease
  • Active liver disease
  • Severe kidney disease
  • Motor disorders (e.g. lower limb fracture, ataxia, etc.)
  • Malignant tumour diseases
  • Physical disability
  • Hb ≤ 80g / L
  • Systolic blood pressure ≤85mmHg
  • History of syncope within 3 months
  • History of supraventricular or ventricular arrhythmia at rest within 3 months.

Key Trial Info

Start Date :

September 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2026

Estimated Enrollment :

104 Patients enrolled

Trial Details

Trial ID

NCT07149935

Start Date

September 1 2024

End Date

December 1 2026

Last Update

September 2 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Renji Hospital

Shanghai, Shanghai Municipality, China, 210007